A mong the many causes of myocardial injury that can lead to congestive heart failure (CHF), myocardial infarction (MI) is the most common in the developed world. 1 The hallmark features of heart failure include reduced contractile function manifested as blunted, slowed, dysynchronous contraction and impaired relaxation. The physiological positive force-frequency relationship and increased myocardial contractile response to increased preload are compromised in heart failure. 2 The failing heart attempts to compensate for injury by various mechanisms, such as myocardial hypertrophy, increasing filling pressure, and enhanced neurohumoral signals, which together drive a feed-forward pathophysiological spiral leading to adverse ventricular remodeling and electric instability. 3 Each of these maladaptive events is associated with loss of myocardial Ca 2+ homeostasis. calmodulin-dependent protein kinase II (CaMKII) are serinethreonine kinases that catalyze ATP-dependent phosphorylation of Ca V 1.2 proteins 15, 16 (Figure 2 ). CaMKII 16 and PKA 17 increase the frequency of prolonged Ca V 1.2 openings, whereas the functional significance of PKC actions at Ca V 1.2 are less clear. 15 These prolonged and frequent Ca V 1.2 channel openings are attributable to mode 2 Ca V 1.2 gating, a biophysical response shared with β-adrenergic receptor (β-AR) agonists, CaMKII, and the dihydropyridine agonist BayK 8644. [16] [17] [18] Phosphorylation by CaMKII or by PKA, the principal kinase activated by β-AR agonists, collaborates with cell membrane potential to enhance the probability of Ca V 1.2 opening. Mode 2 gating appears to underlie I Ca facilitation, a dynamic pattern of increasing peak I Ca and slowed I Ca inactivation. 19 Mode 2 gating and I Ca facilitation are proarrhythmic, in part, by favoring early afterdepolariazations (EADs). 16, 20, 21 Elevated [Na + ] i and altered NA + channel properties is present in failing myocardium from humans. [22] [23] [24] [25] Changes in [Na + ] i may have a large impact on [Ca] 2+ i homeostasis. 26 Small increases in [Na + ] i may increase Ca 2+ influx via reverse-mode NCX during systole and limit Ca 2+ extrusion via forwardmode NCX during diastole, leading to increased subsarcolemmal [Ca] 2+ i . 27, 28 Therefore, increased [Na + ] I levels lead to Ca 2+ overload, contributing to arrhythmias and impaired diastolic function. 22 The major pathway for Na + influx in cardiomyocytes is through voltage-gated Na + channels, primarily Na V 1. 5 , which open and close rapidly (1-10 ms) to trigger the upstroke of action potential depolarization in working myocardium. CaMKII associates with and phosphorylates the Na V 1.5 α-subunit at a "hot spot" in the cytoplasmic I-II linker domain, an event that promotes a noninactivating, long-lasting component of I Na (I NaL ) and arrhythmia-triggering EADs and delayed afterdepolarizations (DADs). 29, 30 CaMKII inhibition reverses the increase of I NaL in heart failure, 31 suggesting that Na V 1.5 is an important target for the antiarrhythmic effect of CaMKII inhibition. 32 [Na + ] i is also maintained by the Na + /K + ATPase pump. It was reported that in failing human hearts, the tissue concentration of the Na + /K + ATPase pumps are reduced. 33 Whether the functional capacity of the Na + /K + ATPase pump in heart failure is altered remains inconclusive because some studies show unaltered maximum transport rate and affinity for Na + in a rabbit heart failure model, 34 whereas the Na + /K + ATPase pump was reduced in a rat heart failure model. 35 
Reduced SR Ca 2+ Release and Increased RyR2 Opening Probability
RyR, the largest ion channel protein (560 kDa), exists as a homotetramer (≈2.2 MDa). The predominant isoform expressed in cardiac muscle is RyR2. 36 RyR2 works as a multiprotein Ca 2+ -release unit in which the RyR2 Ca 2+ channel is composed of 4 membrane-spanning subunits 37 coupled to various regulatory proteins. Calsequestrin, triadin 1, and junctin bind to RyR2 at the luminal SR membrane face, where they transmit Figure 1 . Ca 2+ homeostasis and excitation-contraction coupling (ECC). The ECC process is initiated when an action potential (AP) excites the myocyte cell membrane (sarcolemma) along its transverse tubules. This depolarization rapidly opens voltage-gated Na + channels (mostly Na V 1.5) that further depolarize the cell membrane, allowing opening of voltage-gated Ca 2+ channels (mostly Ca V 1.2). Inward Ca 2+ current triggers opening of ryanodine receptor 2 (RyR2) channels by a Ca 2+ -induced Ca 2+ release process, resulting in coordinated release of sarcoplasmic reticulum (SR) Ca 2+ that contributes the major portion of the myofilament-activating increase in [Ca] 2+ i . The Ca 2+ released from the SR binds to troponin C of the troponin-tropomyosin complex on the actin filaments in sarcomeres, facilitating formation of cross-bridges between actin and myosin and myocardial contraction. Voltage-gated K + channels open to allow an outward current that favors AP repolarization, establishing conditions required for relaxation. Relaxation occurs when Ca 2+ is taken back up into the SR through the action of the SR Ca 2+ adenosine triphosphatase SERCA2a and is extruded from the cell by the sarcolemmal Na + and Ca 2+ exchanger (NCX). SERCA2a is constrained by phospholamban (PLN) under resting conditions. by guest on September 2, 2013 http://circres.ahajournals.org/ Downloaded from information about SR Ca 2+ content to RyR2. 38 It is known that congenital mutations in RyR2, calsequestrin, and triadin can cause increased SR Ca 2+ leak, disorganized diastolic Ca 2+ release, arrhythmias, and sudden death. 39, 40 Under physiological conditions, RyR2 opening probability is increased by the cytoplasmic Ca 2+ trigger from I Ca . 41 RyR2 activity is also regulated by multiple factors, including PKA, CaMKII, protein phosphatases 1 and 2A, calmodulin, and FKBP12.6, which are associated with the cytoplasmic face of RyR2. Marks et al 42 demonstrated that PKA phosphorylates RyR2, which enables the "fight-or-flight" response by increasing RyR2 opening probability and [Ca] 2+ i . 43 They also showed that hyperphosphorylation of RyR2 by PKA (at serine 2808) caused an FKBP12.6-RyR2 dissociation and increased RyR2 opening probability and SR Ca 2+ leak in human 42, 44 and animal models of CHF. [45] [46] [47] [48] In addition, their results also suggest that improved cardiac function by β-AR antagonist drugs in the failing human heart is associated with restoration of FKBP12.6 levels and repair of RyR2 channel leak. 44 However, other groups reported conflicting results that phosphorylation at a single site including serine 2809 does not alter RyR2 function 49 and that phosphorylation at the S2808 site does not mediate β-AR agonist-induced cardiac response 50, 51 or dysfunction after MI. 52 These highly controversial results 53 indicate that alternative mechanisms also may be important for RyR2 dysfunction in heart failure.
CaMKII is activated by β-AR agonist stimulation 54 and increased reactive oxygen species (ROS) 55 and can phosphorylate RyR2 at least 2 sites, serine 2809 and serine 2814 (S2814), 56, 57 although the 2814 site appears to be preferred. 57 CaMKII-dependent RyR2 phosphorylation increases diastolic SR Ca 2+ release. 58 Mice genetically lacking S2814A have an impaired force-frequency relationship 59 and are resistant to MI-induced heart failure and arrhythmias. 60, 61 It also was shown that oxidative stress generated in the failing heart could directly alter RyR2 function by posttranslational modification, causing its increased sensitivity to activation by luminal Ca 2+ . 62 A growing body of evidence suggests that reduced Ca 2+ release in failing cardiomyocytes is a result of increased and improperly regulated activity of multiple Ca 2+ -handling proteins, including Ca V 1.2, Na V 1.5, and RyR2, all of which appear to be targets of CaMKII.
Impaired Ca 2+ Sequestration During Diastole
To achieve relaxation, cytosolic Ca 2+ must be sequestered, mainly to the SR by SERCA2a. 9 Diastolic [Ca] 2+ i is increased Regulation of Ca 2+ homeostasis involves a multitude of Ca 2+ -binding proteins and enzymes, including Ca 2+ -dependent and calmodulin-dependent protein kinase II (CaMKII), protein kinase C (PKC), protein kinase A (PKA), and S100A1. CaMKII catalyzes phosphorylation of voltage-gated Ca 2+ channels (mostly Ca V 1.2 in ventricle) to increase Ca 2+ entry, catalyzes ryanodine receptor (RyR2) phosphorylation to increase Ca 2+ release, catalyzes phosphorylation of voltage-gated Na + channels (mostly Na V 1.5 in ventricle) to increase subsarcolemmal [Na + ] i , which decreases the driving force for Ca 2+ extrusion by the Na + /Ca 2+ exchanger (NCX), and catalyzes PLN phosphorylation to reduce the inhibitory activity of PLN on SERCA2a. In general, the increased phosphorylation of these proteins by CaMKII increases Ca 2+ influx and storage by the sarcoplasmic reticulum (SR), which leads to increased systolic [Ca] 2+ i and increased rate and magnitude of force (pressure) generation and improved lusitropy. PKA is activated by β-AR agonists and catalyzes phosphorylation of the same Ca 2+ regulatory proteins modified by CaMKII, but at different amino acids. Classical PKC isoforms are activated downstream to a variety of G-protein-coupled receptors and are activated by increased [Ca] 2+ in human heart failure, a condition that is likely related, at least in part, to defects in cytosolic Ca 2+ removal. 63 Taken together with loss of physiological SR Ca 2+ release, elevated diastolic [Ca] 2+ i results in reduced contractile force, impaired relaxation, and abnormal force-frequency relationship in human heart failure. The sarcomere is the primary functional unit of cardiac muscle that is responsible for contraction and force generation. Failing myocardium is marked by spontaneous diastolic SR Ca 2+ release, leading to spontaneous and highly variable diastolic sarcomere contractions, which significantly reduces contractile force 64, 65 and contributes to the loss of inotropic effects in CHF. 65 SR Ca 2+ uptake is impaired in the failing human heart, 66, 67 an outcome that is attributable to several mechanisms. First, there is reduced expression and activity of SERCA2a in the failing human heart. 68, 69 However, in some human failing hearts, SERCA2a expression or activity is normal. 70, 71 Overexpression of SERCA2a can restore the Ca 2+ handling and the contractile function in animal models 72 and in human heart failure, 73, 74 suggesting that repairing SERCA2a expression may be a viable therapy for CHF. Defects in SR Ca 2+ release may be attributable to loss of normal "gain" of ECC, a condition in which a given I Ca trigger elicits a lesser amount of SR Ca 2+ release. 75 Comparisons of ECC gain require experimental conditions that control for SR Ca 2+ content. Nevertheless, failing human cardiomyocytes may have preserved fractional SR Ca release 13 despite reduced SR Ca 2+ pump activity, SR Ca 2+ content, and systolic [Ca] 2+ i transients, suggesting that defects in ECC gain are not an obligate aspect of failing myocardiocytes.
Second, reduced SR Ca 2+ uptake could be attributable to increased inhibitory activity of PLN. 76, 77 PLN inhibits SERCA2a in its dephosphorylated form, whereas in its phosphorylated form (by PKA at serine-16 and CaMKII at threonine-17) 78 PLN assembles into a pentamer that lacks SERCA2a inhibitory activity.
Multiple studies suggest that phosphorylation of PLN is decreased in the failing human heart, accounting for increased inhibition of SERCA2a. 77, 79 For example, phosphorylation of PLN at threonine 17 is decreased in ventricular myocardium because of increased dephosphorylation by protein phosphatase 2B, also called calcineurin, despite increased activity of CaMKII in failing myocardium. 80 PLN phosphorylation at serine 16 is decreased because of increased activity of type 1 protein phosphatase in the failing human heart. 77 Several mutations in the human PLN gene (such as R9L, R9H, and L39stop) 81 have been identified that provide important insights into PLN regulation of SERCA2a. Two mutations (R9C and R14del) result in enhanced inhibition of SERCA2 by PLN, partly because of decreased PKA-mediated phosphorylation. 82, 83 The phenotypes of R9C or R14del carriers include dilated cardiomyopathy and premature death. 82, 83 Another human mutation causing loss of function of PLN (Leu39stop) and uninhibited SERCA2a activity also results in dilated cardiomyopathy and premature death. 84 Genetic manipulation of PLN in mouse models yielded similar and contrasting results compared with human mutations. PLN knockout mice showed enhanced cardiac contractile function with increased affinity of SERCA2a for Ca 2+ , consistent with the concept that PLN downregulates myocardial contractility by suppressing SERCA activity. 85 PLN knockout prevented heart failure in a mouse model of dilated cardiomyopathy caused by deficiency of the muscle-specific LIM protein. 86, 87 Gene therapy with antisense against PLN improved contractile and diastolic function in isolated failing human cardiomyocytes. 88 However, PLN knockout in mice with severe cardiomyopathy attributable to transgenic overexpression of CaMKII improved SR Ca 2+ content and myocardial contraction, but nevertheless increased mortality, mitochondrial Ca 2+ , and myocardial cell death. 89 Taken together, these studies of mice and humans suggest that SERCA2a/PLN activity needs to be maintained within certain boundaries to support physiological function and prevent cardiomyopathy.
Another emerging regulator of SERCA activity is the Histidine-rich Ca 2+ -binding protein (HRC), a low-affinity and high-capacity Ca 2+ -binding protein located in the SR lumen. 90 HRC also affects RyR function through its binding to triadin, and it was suggested that HRC may mediate a cross-talk between SR Ca 2+ uptake and release. A human HRC variant (S96A) with substitution of Ala in position 96 is associated with life-threatening ventricular arrhythmias in dilated cardiomyopathy patients, accompanied by a reduced [Ca] 2+ i transient and a prolonged decay time. 91 Transgenic overexpression of HRC in the heart decreases SR Ca 2+ uptake rates, suggesting that HRC inhibits SERCA2a and intracellular Ca 2+ cycling and promotes progression to heart failure. 92 These studies suggest an important role of HRC in maintaining Ca 2+ homeostasis in the SR.
The relative contribution of NCX to cytoplasmic Ca 2+ sequestration is increased in failing myocardium, probably because of the decreased SR Ca 2+ uptake. 93 Expression of NCX in human CHF has been reported to increase 10 or to be unchanged. 94 Because subsarcolemmal [Na + ] i is increased in failing ventricular myocytes, NCX current (I NCX ) shifts from inward to outward, 95 which contributes to prolonged cytoplasmic [Ca] 2+ i transients, Ca 2+ overload, and diastolic dysfunction. 22, 95, 96 Thus, enhanced I NCX may be adaptive to defects in SERCA2a/PLN in CHF while also contributing to subsarcolemmal [Na + ] i and [Ca] 2+ i overload in CHF.
Adenosine Triphosphate, Mitochondrial Ca 2+ Uptake, and Retention
Adenosine triphosphate (ATP) is the predominant form of readily available energy in myocardium. 97 The Ca 2+ concentration gradient between the extracellular and intracellular environments is massive, with approximately 10 000-fold higher extracellular than bulk cytoplasmic (≈100 nmol/L) 98 [Ca] 2+ i . Maintaining Ca 2+ homeostasis constitutes a major ATP cost for cardiomyocytes. SERCA2a and the Na + -K + ATPase are among the largest energy-consuming proteins. 99 A proper equilibrium between Ca 2+ cycling and ATP production must be maintained to ensure proper intracellular Ca 2+ handling and a physiological range of myocardial performance. 100, 101 Mathematical modeling 102, 103 and experiments in excised myocardial cell membrane patches using the ATP-sensitive K + current (I KATP ) as a readout for subsarcolemmal ATP 102,103 support a view that ATP availability can be rate-limiting under stress conditions because of high local ATP consumption and compartmentalization. Thus, it is plausible that subcellular domains of ATP deficiency contribute to myocardial dysfunction in CHF.
by guest on September 2, 2013 http://circres.ahajournals.org/ Downloaded from CHF is associated with abnormal energy metabolism, including decreased energy production and impaired energy utilization, [104] [105] [106] which appear to adversely affect [Ca] 2+ i homeostasis. 100, 106 Reduced ATP/ADP ratio, attributable to mitochondrial dysfunction, caused impaired function of SERCA2a in animal models of CHF. 107 However, Ca 2+ transport regulates ATP production in mitochondria. 108, 109 Some validated clinical therapies for CHF improve myocardial energetics and normalize [Ca] 2+ i homeostasis. For example, β-AR antagonists were designed by Sir James Black, in part, to reduce myocardial O 2 consumption with a goal of preventing MI. 110 β-Blockers, which decrease energy consumption, have been shown to normalize the contractile function and Ca 2+ handling in failing human hearts. 111, 112 Left ventricular assist devices, which decrease the workload of the heart, improve Ca 2+ handling in CHF patients. 14, 113 Restoration of mitochondrial Ca 2+ homeostasis by unloading mitochondrial Ca 2+ restored cardiac energetics, including ATP synthesis. 114 Thus, CHF appears to be a condition that arises, at least in part, by interrelated defects in [Ca] 2+ i homeostasis and metabolism, and successful CHF therapies often restore physiological [Ca] 2+ i homeostasis and metabolism.
Mitochondrial Ca 2+ Regulates Cell Metabolism and Cell Death
Mitochondria comprise approximately 20% to 30% 115 of cardiac mass, where they are essential for providing ATP to meet the heightened energy demand for cardiac function. Ca 2+ appears to be a critical second messenger for communicating cellular energy demands to mitochondria for the purpose of matching ATP production by oxidative phosphorylation with metabolic requirements. 109 Oxidative phosphorylation is a Ca 2+ -regulated process because Ca 2+ increases the activity of key tricarboxylic acid dehydrogenases involved in producing reducing equivalents (NADH/NADPH) for electron transport. 116 Metabolic regulation by mitochondrial Ca 2+ uptake, however, is not limited to the effects on dehydrogenases. The aspartate/glutamate exchangers located at the inner mitochondrial membrane have Ca 2+ -binding domains, which support increased ATP production in response to local and temporal Ca 2+ signals. 117, 118 Furthermore, the close physical association between mitochondria, SR, and plasma membrane Ca 2+ channels ensures prompt Ca 2+ transfer to the mitochondrial matrix, which stimulates oxidative phosphorylation in response to activation of ATP-consuming processes in the cytosol. 119, 120 Compared with the SR, mitochondria have a lower affinity but a higher capacity for taking-up Ca 2+ . Mitochondria may constitute an important buffer for cytoplasmic Ca 2+ , 119, 121 but excessive accumulation of mitochondrial Ca 2+ causes mitochondrial damage and myocardial death 122 (Figure 3 ).
Excessive mitochondrial [Ca] 2+ ([Ca] 2+
m ) and ROS 123 trigger mitochondrial permeability transition pore (mPTP) opening and subsequent dissipation of inner mitochondrial membrane potential (Δψm) and release of apoptotic mediators such as cytochrome C, 124 leading to cell death. 125, 126 The mPTP appears to be an important but incompletely understood target for CaMKII. 127 Our group recently reported that cardiomyocytes from mice with transgenic expression of a mitochondrial-targeted CaMKII inhibitory protein 128 were able to sustain higher mitochondrial Ca 2+ entry before mPTP opening and were resistant to programmed cell death from ischemia/reperfusion-related, catecholamine-related, and MI-related injury, suggesting that CaMKII promotes mPTP opening and myocardial death 129 (Figure 3) .
Mitochondria are considered a key source for pathological increases in ROS, mainly as a result of electron transport chain uncoupling at the level of complexes I and III. 123, 130 Oxidative stress could damage mitochondrial DNA and proteins by forming oxidative adducts, leading to mitochondrial dysfunction, impairing myocardial energetics in heart failure. However, in heart failure, impaired mitochondrial bioenergetic function with decreased electron transport systems could cause increased oxidative stress. 131, 132 Thus, mitochondrial dysfunction and ROS are tightly linked elements of an interdependent feed-forward circuit that promotes the pathogenesis of heart failure.
Mitochondrial Ca 2+ Uniporter
The mitochondrial Ca 2+ uniporter (MCU) is a Ca 2+ -selective channel residing in the inner mitochondrial membrane and the major mitochondrial Ca 2+ entry pathway. [133] [134] [135] MCU can be located in close proximity to the SR 136 and thus is exposed to high [Ca] 2+ (≈20-50 μmol/L). 137 Although the existence of the MCU was established more than 50 years ago, 138 it was not until recently that the molecular identity of MCU was discovered. MCU consists of 2 predicted membrane-spanning domains with a linker/pore loop to form a functional channel. 134, 135 Overexpression of MCU increases cell death in response to challenge by proapoptotic stimuli, 135 whereas suppressing MCU with Ru360, a pharmacological antagonist related to ruthenium red, protects against ischemia-reperfusion injury. 139 We recently found that MCU is a phosphorylation substrate for CaMKII and that CaMKII-mediated increases in MCU current (I MCU ) required serines 57 and 92 when MCU was expressed heterologously, whereas mitochondrial-targeted CaMKII inhibition reduced I MCU in myocardium. 129 The role of CaMKII signaling to MCU in heart failure is uncertain at this time, but mitochondrial CaMKII inhibition is protective against myocardial death in response to ischemia-reperfusion injury, MI, and toxic doses of isoproterenol, 129 suggesting protective effects of mitochondrial CaMKII inhibition may be mediated, at least in part, by reducing I MCU .
The MICU1 is a MCU binding partner that has a single membrane-spanning domain and 2 Ca 2+ -binding EF-hand domains. 134, 139 Some recent data suggest that MICU1 is essential for setting the Ca 2+ dependence of I MCU 135, 140 and preserving normal [Ca] 2+ m by acting as a gatekeeper for Ca 2+ uptake and preventing mitochondrial Ca 2+ overload and excessive oxidative stress. 141 In addition, MCU regulator-1 also was recently shown to be required for MCU-dependent mitochondrial Ca 2+ uptake and maintenance of normal cellular bioenergetics. 142 Thus, MCU appears to be a Ca 2+ -regulated and CaMKIIregulated ion channel associated with various accessory protein subunits.
Few studies have investigated whether or how mitochondrial Ca 2+ uptake, transport, and homeostasis are altered in heart failure. Limited indirect evidence suggests that mitochondrial Ca 2+ uptake is reduced in failing cardiac myocytes because there is reduced open probability of Ca 2+ conductance pathways in mitoplasts isolated from failing myocardium and decreased Δψm, 143 the electric driving force for mitochondrial Ca 2+ uptake. 106 There is an emerging view that defective cytosolic Na + and Ca 2+ homeostasis affects mitochondrial Ca 2+ transport in heart failure. Mitochondrial Ca 2+ efflux is mainly enabled by the mitochondrial Na + /Ca 2+ exchanger. 144 Elevated [Na + ] i stimulates mitochondrial Na + /Ca 2+ exchanger and mitochondrial Ca 2+ efflux and reduces steady-state [Ca] 2+ m . 144 Thus, mitochondria are a critical interface between Ca 2+ metabolism and are key determinants of myocardial survival in response to clinically relevant forms of pathological stress. A growing body of evidence suggests that mitochondria play a central role in heart failure.
Transverse Tubules
Transverse tubules are deep invaginations of the ventricular myocyte cell membrane (sarcolemma), where voltage-gated Ca 2+ channels are richly expressed and tightly coupled with SR RyR2, forming dyads to enable Ca 2+ -induced Ca 2+ release. There is emerging evidence that normal transverse tubular ultrastructure is disrupted in heart failure. 145, 146 Transverse tubules can become spatially dispersed, leaving RyRs "orphaned" from their dyadic association with Ca V 1.2, 147 which impairs Ca 2+ -induced Ca 2+ release. In addition, Ca 2+ transients in these regions will depend on Ca 2+ diffusion and propagated Ca 2+ release, thus contributing to dysynchronous Ca 2+ sparks, inefficient ECC, and a propensity toward arrhythmias. Recent studies suggest that junctophilin-2 may play a crucial role in maintenance of normal transverse tubular ultrastructure 145, 148 and association of Ca V 1.2 with RyR2, 148, 149 whereas targeted suppression of microRNA, which inhibits junctophilin, prevents disruption of T-tubule structure and transition to heart failure from hypertrophy. 150 β-AR antagonists 151 and sildenafil 152 can defend against transverse tubular disruption in animal models of heart failure. Thus, improved understanding of the interface between membrane and regulatory cytoskeletal proteins may lead to new therapeutic targets to preserve cellular architecture that is required for physiological Ca 2+ homeostasis.
Myofilament and Cytoskeletal Proteins
Abnormal Ca 2+ homeostasis and myofilament function impair cardiac contractile function and trigger ventricular arrhythmias in heart failure. 153 Ankyrins are adapter proteins that attach membrane proteins to the spectrin-actin-based membrane skeleton and thus are intimately involved in ion channel and transporter signaling complexes in the cardiovascular system. 154 Ankyrin dysfunction has been linked with abnormal ion channel and transporter membrane organization and human arrhythmias. 155, 156 Genetic defects in ankyrins cause altered Na + and Ca 2+ transport and enhanced RyR2 openings, contributing to loss of [Ca] 2+ i homeostasis, 157 activation of CaMKII, and arrhythmias. 158 It was recently reported that ankyrin B plays a cardioprotective role against ischemia-induced cardiac dysfunction and ankyrin-B levels are decreased in human heart failure. 159 Titin is a large myofilament protein that spans half of the sarcomere and functions as a molecular spring that provides passive stiffness to cardiac myocytes. 160 Titin isoform composition and phosphorylation regulate myocardial diastolic function. 160 Titin expression was reported to be increased in pressure-overload hypertrophy but was decreased in decompensated CHF, 161, 162 suggesting that titin could contribute to the loss of compliance and decreased contractile function featured in heart failure. Titin knockout mice demonstrated reduced SR Ca 2+ uptake accompanied by reduced levels of PLN and SERCA2a, and these mice had development of cardiac hypertrophy and heart failure. 163 CaMKII phosphorylates titin and modulates passive force generation in normal and failing myocardium. 164 Deranged CaMKII-dependent titin phosphorylation occurs in heart failure and contributes to altered diastolic stress. 164 These findings suggest that titin is a participant in Ca 2+ -related defects in heart failure, and suggest that titin could emerge as a target for future heart failure therapies.
Dystrophin is a cytoplasmic protein and a crucial part of the dystroglycan complex, which consists of tightly associated transmembrane and cytoskeletal proteins that serve to connect the cytoskeleton to the extracellular matrix. 165 Mutation of the dystrophin gene and absence of dystrophin cause Duchnne muscular dystrophy (DMD), a fatal X-linked disease, 166 which results in a skeletal as well as a dilated cardiomyopathy. Cardiac involvement including heart failure accounts for 20-30% of the mortality in DMD patients. 167 An MDX mouse, which is a model of DMD and lacks the protein dystrophin, has decreased levels of SR luminal Ca 2+ -binding proteins, 168 decreased SERCA2a expression, 169 and an increase in resting [Ca] 2+ i . 170 Patients with DMD are at increased risk for fatal cardiac arrhythmias. 167, 171 MDX mice were shown to have "leaky" RyR2 because of S-nitrosylation of the channel and Figure 3 . A scenario for mitochondrial Ca 2+ overload, impaired metabolism, and cell death in heart failure. The mitochondrial Ca 2+ uniporter 132 is a Ca 2+ -selective channel residing in the inner mitochondrial membrane. Mitochondrial Ca 2+ uniporter (MCU) is a phosphorylation substrate for Ca 2+ -dependent and calmodulindependent protein kinase II (CaMKII). Mitochondrial CaMKII inhibition reduces MCU current, increases mitochondrial Ca 2+ retention capacity, and is protective against myocardial death in response to ischemia-reperfusion injury, myocardial infarction (MI), and toxic doses of isoproterenol. Excessive mitochondrial Ca 2+ and reactive oxygen species (ROS) trigger mitochondrial permeability transition pore (mPTP) opening, leading to cell death. Mitochondria Ca 2+ overload also promotes ROS generation, which could oxidize CaMKII (ox-CaMKII) and cause sustained activation of CaMKII. The ox-CaMKII could enhance MCU activity and further increase mitochondrial Ca 2+ overload, promoting mPTP opening and impairing energy metabolism in heart failure. At the same time, myocardial energy deficiency could adversely affect [Ca] 2+ i homeostasis.
FKBP 12.6 depletion. 172 Suppressing the RyR2-mediated diastolic SR Ca 2+ leak by inhibiting FKBP 12.6 depletion prevented any fatal sudden cardiac arrhythmias in DMD mice, suggesting that leaky RyR2 triggers ventricular arrhythmia in DMD. 172 Recent studies show that CaMKII inhibition or interbreeding into a genetic background with a knock-in RyR2 S2814A mutation that is resistant to CaMKII prevents arrhythmogenic Ca 2+ waves and ventricular tachycardia in MDX mice, 173 suggesting that CaMKII phosphorylation at S2814A of RyR2 contributes to the arrhythmia in MDX mice and possibly in DMD patients. Combined, these studies suggest that myofilament and cytoskeletal proteins are intimately involved in Ca 2+ homeostasis and contribute to pathogenesis of heart failure and arrhythmias.
Alterations in Regulatory Mechanisms in Heart Failure

Ca 2+ and Calmodulin-Dependent Protein Kinase II
CaMKII is a multifunctional serine-threonine protein kinase that is abundant in nerve and muscle. There are 4 different CaMKII encoding genes, with each encoding a distinct CaMKII isoform (α, β, γ, δ). CaMKIIδ appears to be the main isoform expressed in the heart, but CaMKIIγ is also present. 174 Whether these 2 main isoforms have selective roles in cardiac pathophysiology is unclear at this point, because there are few studies investigating the role of CaMKIIγ. Transaortic banding induced increased expression of both CaMKIIδ and CaMKIIγ isoforms 175 and conditional double-knockout of CaMKIIδ and CaMKIIγ caused decreased phosphorylation of target proteins. 164 A recent study suggests that CaMKIIγ is enriched in mitochondria. 176 CaMKII connects intracellular Ca 2+ signaling to ECC and regulates both SR Ca 2+ uptake and release ( Figure 2 ). CaMKII acts on multiple Ca 2+ homeostatic proteins involved in ECC, 32 including voltage-gated Ca 2+ channels, 16 RyR2, 177 and PLN. 178 In general, CaMKII-mediated phosphorylation of Ca 2+ homeostatic proteins enhances their activity and promotes performance of physiological events such as ECC and fight-or-flight mechanical and heart rate responses. CaMKII consists of stacked hexamers and each monomer consists of an N-terminus catalytic domain and a C-terminus association domain that flank a core regulatory domain. 179 The "hypervariable" region located between the association and regulatory domains is likely responsible for tuning the Ca 2+ sensitivity of CaMKII activation. 179 CaMKII is activated when [Ca] 2+ i binds to calmodulin (CaM), causing conformational changes that release the catalytic domain from the negative regulation by the autoinhibitory region of the regulatory domain. 179 Under diastolic, resting [Ca + ] i in the presence of low ROS, CaMKII is enzymatically inactive because of the binding of catalytic domain to an autoinhibitory region. Sustained activation of CaMKII by binding to calcified calmodulin (Ca 2+ / CaM) leads to threonine 287 autophosphorylation (the numbering varies slightly between isoforms), CaM trapping, and CaMKII activation that is autonomous from Ca 2+ /CaM (Figure 4 ). 180 Ca 2+ /CaM autonomous (constitutively active) CaMKII is also generated by oxidation of paired regulatory domain methionines (281/282). 55 In this setting, oxidized CaMKII resets its Ca 2+ sensitivity so that lower levels of intracellular Ca 2+ are required for initial activation. 181 Thus, both threonine 287 autophosphoryation and methionine 281/282 oxidation can convert CaMKII into a constitutively active enzyme. The constitutively active forms of CaMKII appear to be particularly effective at driving myocardial disease phenotypes. 21, [182] [183] [184] Thus, CaMKII is a highly regulated i binds to calmodulin, causing CaMKII to assume an active, extended conformation. Sustained binding to calcified calmodulin (Ca 2+ /CaM) leads to threonine 287 autophosphorylation and sustained CaMKII activation. Oxidation of paired regulatory domain methionines (281/282) also causes sustained activation of CaMKII as oxidized CaMKII resets its Ca 2+ sensitivity so that lower levels of intracellular Ca 2+ are required for initial activation. Thus, both threonine 287 autophosphoryation and methionine 281/282 oxidation can convert CaMKII into a constitutively active enzyme to drive myocardial disease phenotypes. signal, but under pathological stress CaMKII undergoes posttranslational modifications that convert it into a Ca 2+ /CaMautonomous enzyme with the potential to promote heart failure and arrhythmias.
Chronic and excessive neurohormonal activation contributing to the progression of CHF cause increased [Ca] 2+ i and ROS, 185, 186 causing sustained activation of CaMKII. Increased myocardial CaMKII activity and expression have been found in various animal models 187, 188 and in patients with heart failure. 189 Mice with myocardial transgenic CaMKII overexpression have development of heart failure and premature sudden death. 190 CaMKII activation by β-AR stimulation causes fetal gene induction, pathological hypertrophy, 54, 191 myocardial apoptosis, 192 arrhythmia, 193 and worsening heart failure after MI. 55 Angiotensin II activates CaMKII by methionine oxidation and promotes cardiomyocyte death, 55, 181 which contributes to sinus node dysfunction, 183 a frequent counterpart to heart failure. Aldosterone activates CaMKII by methionine oxidation and CaMKII activation by aldosterone leads to increased death after MI by increasing the propensity to myocardial rupture. 182 Intriguingly, excessive oxidized CaMKII activates a myocyte enhancer factor-2 transcriptional signaling pathway to increase myocardial expression of matrix metalloproteinase-9 that contributes to myocardial matrix instability and sudden death attributable to postmyocardial infarction cardiac rupture. 182 We recently found that hyperglycemia also leads to increased methionine 281/282 oxidized CaMKII in diabetic patients and in mice, and increased oxidized CaMKII is a necessary signal for diabetes-associated excess mortality in a mouse model of MI. 184 We found that ROS was increased in cardiac myocytes exposed to hyperglycemia and that mitochondrial-targeted antioxidant therapy or a knock-in mutation of CaMKIIδ to prevent oxidative activation (M281/281V) were both effective at preventing excess diabetes-attributable mortality after MI. 184 Importantly, CaMKII inhibitors significantly improved the force-frequency relationship in failing human cardiomyocytes. 194 CaMKIIδ −/− knockout mice are resistant to myocardial hypertrophy and pressure overloadinduced heart failure, 195, 196 and mice with transgenic myocardial CaMKII inhibition are resistant to heart failure from MI. 54 Taken together, this evidence indicates that CaMKII plays an important role in connecting upstream signals, such as neurohumoral activation, hyperglycemia, ischemic injury and infarction with defective Ca 2+ signaling, and downstream pathological outcomes important for CHF.
Protein Kinase A
PKA is the principal upstream kinase activated by β-AR agonists. There are multiple β-AR subtypes, including β 1 -AR, β 2 -AR, and β 3 -AR. 197, 198 β-ARs belong to the large family of G-protein-coupled receptors with 7 transmembrane domains 199 and contain phosphorylation sites 200 that serve as targets for protein kinases, including PKA and PKC. 201 The binding of circulating adrenergic amine agonists to β-ARs activates adenylate cyclase and simulates cAMP production to release the catalytically active subunit of PKA.
PKA, in turn, catalyzes phosphorylation of multiple Ca 2+regulatory proteins, including PLN, L-type Ca 2+ channels, and RYR2. Under physiological conditions, activation of the β-AR signaling pathway through PKA stimulates Ca 2+ influx and increases SR Ca 2+ uptake and storage by the SR, leading to increased systolic [Ca] 2+ i transients and thus increased contractile function and lusitropy. 4 However, in the failing heart, chronically elevated adrenergic agonist activity leads to downregulation of β 1 -AR signaling with decreased β 1 -AR density 202, 203 and uncoupling of β 2 -AR from downstream effector molecules, including Ca 2+ -regulatory target proteins such as PLN, 204 leading to inefficient ECC and decreased contractile function. These changes impair the ability of the failing heart to increase contractility to meet hemodynamic demands.
Widely established benefits of β-AR antagonist drugs in treating heart failure 44 strongly support that altered β-AR signaling is maladaptive and promotes heart failure progression. However, the mechanisms of therapeutic benefit for β-AR antagonist drugs are likely to be diverse. β-AR antagonists preserve transverse tubular ultrastructure, 151 reverse RyR2 hyperphosphorylation, 44, 204 and decrease SR Ca 2+ leak, 44, 205 leading to increased contractility in heart failure. In addition, β-AR agonist stimulation causes apoptosis via activation of a mitochondrial death pathway, 206 whereas β-AR antagonists such as carvedilol can protect mitochondria from oxidative stress-induced mPTP opening. 207, 208 PKA-dependent β-AR signaling desensitizes after sustained β 1 -AR agonist stimulation. 209 In contrast, CaMKII signaling in ECC is persistent and may be necessary to sustain positive inotropic actions of prolonged catecholamine signaling. 210 Epac is a guanine nucleotide exchange protein that directly binds to and is activated by cAMP in parallel to the classical PKA signaling pathway. Epac was shown to mediate β-AR-induced cardiomyocyte hypertrophy 210, 211 and arrhythmias, 212 to modulate cardiac nuclear Ca 2+ signaling by increasing nuclear Ca 2+ through phospholipase C, inositol trisphosphate, and CaMKII, and to activate the transcription factor MEF2. 213 A recent study demonstrated that Epac may mediate cardioprotection from cell death induced by β-AR activation. 214 Thus, β-AR stimulation activates multiple signaling pathways, including cAMP/PKA, cAMP/Epac, and the CaMKII pathway. In our view, it is not yet clear how much of the therapeutic benefit of β-AR antagonist drugs is attributable to reduced PKA activity or what portion is attributable to reduction in the activity of other downstream signals, such as CaMKII.
Protein Kinase C
PKC is a family of serine-threonine protein kinases that are present in a wide variety of tissues, including myocardium. PKCα is the most abundantly expressed isoform of the myocardial PKC family. Receptors for activated C kinase are isoform-selective anchoring proteins for PKCs. 215 Receptors for activated C kinase are important for determining the subcellular localization of PKC isoenzymes. 215 PKCα plays an important role in regulating myocardial contractility. For example, mice with PKCα deletion demonstrate an increase in [Ca] 2+ i transients and contractility, whereas overexpression of PKCα diminishes contractility. 216 PKCα knockout mice are protected from pressure overload-induced heart failure and from dilated by guest on September 2, 2013 http://circres.ahajournals.org/ Downloaded from cardiomyopathy induced by deleting the gene-encoding muscle LIM protein (Csrp3), and are protected from cardiomyopathy associated with overexpression of type 1 protein phosphatase. 216 One experimentally validated pathway for PKCα action to decrease [Ca] 2+ i transients is that PKCα suppresses SERCA2a activity by phosphorylating inhibitor-1, resulting in increased type 1 protein phosphatase activity and dephosphorylation of PLN. 216 Decreased SERCA2a activity thus reduces SR Ca 2+ load, leading to reduced Ca 2+ release during systole, hence reducing contractility. Other PKC isoforms (δ) and (E) may play a significant role in promoting hypertrophy. 217, 218 Taken together, these results from animal models support a potential role for PKC in promoting heart failure progression. S100A1 S100A1 belongs to the S100 protein family, a group of EFhand-containing Ca 2+ -binding proteins. S100A1 shows highest expression in human cardiac muscle and is preferentially expressed in the left ventricle. S100A1 has a molecular weight of 10.4 kDa and contains 2 functional EF-hand Ca 2+ -binding motifs. On Ca 2+ binding, S100A1 undergoes a conformational change to expose a hydrophobic pocket for binding to target proteins. 219 The Ca 2+ binding affinity of S100A1 is tightly regulated by posttranslational modifications, including S-nitrosylation and S-glutathionylation of a cysteine residue in the C-terminal region. [220] [221] [222] Either modification enhances Ca 2+ affinity by several orders of magnitude, which augments the ability of S100A1 to sense Ca 2+ oscillations over a wide dynamic range. 220-222 S100A1 has emerged as a key regulator of Ca 2+ cycling and cardiac contractile function. 220,223 S100A1 enhances SR Ca 2+ uptake and increases SR Ca 2+ content. 109,223 S100A1 also directly regulates RyR2 function. 223, 224 More recently, S100A1 was found to reside in mitochondria, where it stimulates ATP synthase (complex V) activity and promotes the adenosine nucleotide translocator function to increase ATP synthesis and mitochondrial ATP efflux in cardiomyocytes. 109, 225 S100A1 knockout mice had impaired contractility and showed enhanced proarrhythmogenic susceptibility to acute β-AR agonist stimulation and pressure overload induced by chronic transaortic constriction. 226, 227 There was impaired SR Ca 2+ uptake, increased SR Ca 2+ leakage, and a reduced SR Ca 2+ load in heart tissues from the S100A1 knockout mice. 228, 229 The S100A1 knockout mice also demonstrated excessive mortality and accelerated CHF after MI, as well as increased post-MI cardiac remodeling. 228, 229 In contrast, mice with myocardial S100A1 overexpression showed enhanced contractile responses to β-AR stimulation, improved [Ca] 2+ i homeostasis, improved survival, and preserved left ventricular function after MI. 229 In human heart samples with dilated and ischemic cardiomyopathy, S100A1 mRNA and protein expression were found to be downregulated. 230, 231 Decreased S100A1 expression levels also were shown in experimental HF animal models and correlated with the severity of heart failure and mortality. 229, 232 These results suggest that S100A1 plays an important role in regulating Ca 2+ cycling and contractile function, whereas loss of S100A1 may contribute to heart failure in the setting of pathological stress.
Calcineurin
Calcineurin, also known as protein phosphatase 2B, is a Ca 2+ /CaM-activated serine-threonine phosphatase and the first Ca 2+ -dependent signaling molecule explicitly linked to myocardial hypertrophy and heart failure. 233, 234 Calcineurin signaling stimulates cardiac hypertrophy 235, 236 and remodeling through activation of the nuclear factor of activated T-cell (NFAT) transcription factor. On calcineurin-mediated dephosphorylation, NFAT translocates to the nucleus and activates cardiac transcription. 237 The calcineurin-NFAT signaling pathway in myocardium appears to be activated only when there are pathological increases in [Ca] 2+ I , whereas it is not activated during physiological hypertrophy induced by exercise or pregnancy, 238 suggesting that calcineurin signaling is tightly coupled with pathological defects in Ca 2+ homeostasis.
There is increased calcineurin activity or expression in animal models 235 and in patients with myocardial hypertrophy and heart failure. 232, 239, 240 Overexpression of calcineurin causes myocardial hypertrophy, heart failure, and premature death. 234, 238 Calcineurin inhibition by cyclosporin prevented hypertrophy in mice genetically predisposed to development of hypertrophic cardiomyopathy and in a rat model of pressure overload-induced hypertrophy. 244 Calcineurin Aβ-knockout mice, with an 80% decrease in calcineurin enzymatic activity in the heart, show decreased hypertrophic responses induced by pressure overload or agonist infusion, including angiotensin II and isoproterenol. 241 Intriguingly, CaMKII expression and activity were increased in calcineurin transgenic mice. 193 CaMKII inhibition improved contractile function, reduced arrhythmias, and decreased mortality in mice with myocardial transgenic overexpression of a constitutively active form of calcineurin without substantially reducing calcineurin-evoked myocardial hypertrophy. 193, 238 We interpret these findings to suggest that myocardial dysfunction and high mortality in calcineurin transgenic mice are, at least in part, attributable to downstream activation of CaMKII and independent of myocardial hypertrophy. The interactions between calcineurin and CaMKII are complex, as highlighted by the finding that CaMKII catalyzed phosphorylation of calcineurin prevents full activation of calcineurin by inhibiting Ca 2+ /CaM binding. Thus, CaMKII may act as an antihypertrophic agent in the context of the calcineurin/NFAT pathway. 243 Overall, these findings support a view that calcineurin is an important regulator of cardiac hypertrophy and heart failure but leave open the question of which downstream events are critical for the cardiomyopathic actions of calcineurin.
Arrhythmias as a Common Cause of Death in Heart Failure
Heart failure, especially in patients with left ventricular ejection fractions less than 30%, is associated with a high rate of arrhythmia-induced sudden death. 244 Various factors appear to enhance the probability of arrhythmias, including defective [Ca] 2+ i homeostasis. Many ion channels respond to loss of normal [Ca] 2+ i homeostasis by contributing to cell membrane hyperexcitability. However, as exemplified by the Cardiac Arrhythmia Suppression Trial (CAST) 245 and Survival with Oral d-Sotalol (SWORD), 246 ion channel antagonist therapies are not effective in preventing sudden death in patients at high risk. In contrast, neurohumoral antagonist drugs that serve as mainstay therapeutics for heart failure, such as β-AR, 247 angiotensin II, 248 and mineralocorticoid receptor antagonists, 249 are effective in reducing sudden death. These findings suggest that signals that modulate ionic currents are better therapeutic targets than ion channels.
Electric Remodeling
Proarrhythmic electric remodeling is a term used to describe multiple changes in ionic currents that collectively lead to action potential and QT interval prolongation and favor arrhythmias in failing ventricular myocardium. Prolongation of the action potential plateau, in particular, contributes to a proarrhythmic substrate for noninactivating components of Na V 1.5 current 30, 250 and Ca V 1.2 channels in a high-activity gating mode. 16 A comprehensive review of electric remodeling in heart failure is beyond the scope of this review but has been published elsewhere. 251 Voltage-gated K currents (I K ) are the major driving force for myocardial membrane repolarization, 252 and failing myocardium is consistently reported to show reduced repolarizing I K that contributes to proarrhythmic action potential and QT interval prolongation. 253 Interestingly, excessive CaMKII activity also contributes to reduced I K in failing myocardium by phosphorylation of the pore-forming α-subunit of the voltage-dependent K + channel 4.3 at Ser 550 , which encodes a class of rapidly inactivating I K , including the transient outward current in the heart. 254 Cardiac ATP-sensitive K + (K AT P ) channels are metabolic sensors activated in response to various forms of cardiac stress, including ischemia and neurohormonal activation, leading to membrane hyperpolarization, decreased action potential duration, and contractility. 255 Hence, K AT P channels play an important role in improving cellular energy efficiency and stress resistance. Association of K AT P with Ankyrin B via the C-terminus of Kir6.2, the pore-forming unit, was shown to be important for K AT P channel trafficking and membrane metabolic regulation. 256 One recent study suggests that CaMKII couples the surface expression of cardiac K AT P channels with Ca 2+ signaling to regulate energy efficiency and stress resistance, because Ca 2+ -dependent activation of CaMKII results in phosphorylation of Kir6.2, the pore-forming subunit, and promotes internalization of K AT P channels. 257 CaMKII also affects trafficking of a variety of voltage-gated K + currents, with the net effect of reducing repolarizing K + current and prolonging the action potential. 258 These findings suggest that [Ca] 2+ i may feed-back to control multiple ionic currents through activation of CaMKII and that excessive CaMKII activity in CHF contributes to the proarrhythmic substrate and the enhanced risk for sudden death in structural heart disease by altering ion channel function and membrane expression.
CaMKII and Arrhythmia
Heart failure is a condition of increased oxidant stress, loss of [Ca] 2+ i homeostasis, and activation of CaMKII. CaMKII exerts proarrhythmic effects through actions at multiple protein targets that are key components of Ca 2+ homeostasis, including CaV1.2, 16,259 NaV1.5, 31, 250 and RyRs 57 ( Figure 5 ). CaMKII increases phosphorylation of a CaV1.2 β-subunit (β 2a ) at Thr498, 259 leading to high-activity mode 2 gating, intracellular Ca 2+ overload, and EADs. 16 Phosphorylation of RyR2 at Ser2814 by CaMKII increases diastolic SR Ca 2+ leak, 57 which is proarrhythmic 260 by triggering DADs. CaMKII acts on Nav1.5, the predominant cardiac voltage-gated Na + channel, and increases I NaL , 30, 31, 250 which prolongs action potential and triggers early EADs. 31, 250 CaMKII inhibition has been shown to prevent or suppress ventricular arrhythmias in myocardial tissues and animal models. 260, 261 This evidence consistently suggests that CaMKII can promote arrhythmias and sudden death, and that CaMKII inhibition can reduce or prevent arrhythmias.
Reverse ECC
Diseased myocardium is nonuniform in ECC, with damaged and nondamaged regions as well as inhomogeneous border zone areas bridging damaged and healthy tissue. Arrhythmogenic contractile waves were observed in nonuniform failing myocardium. 262 A potential mechanism underlying this phenomenon is reverse ECC, 263 a process during which abnormal contractions of damaged regions cause regional increase of [Ca] 2+ i , leading to arrhythmogenic contractile waves. Aftercontractions appear to be initiated by the weak and damaged region during regular contractions and propagate into neighboring myocardium. 264 These contractile waves are likely attributable to mechanical i , and delayed afterdepolarizations (DADs). CaMKII phosphorylates Na + channels (Na V 1.5) and enhances the long-lasting late I Na (gain of function), promoting EADs and increasing subsarcolemmal [Na + ] i to favor DADs. CaMKII favors phosphorylation of ryanodine receptor (RyR2) to increase sarcoplasmic reticulum (SR) Ca 2+ leak, which shifts Na + /Ca 2+ exchanger (NCX) to a forward mode, causing DADs. CaMKII contributes to arrhythmogenic structural features of injured myocardium by promoting myocyte death and collagen deposition. effects of damaged myocardium, such as stretching and release, and regional elevation of [Ca] 2+ i as a result of damage. 265 When cardiac muscle is damaged, intracellular Ca 2+ waves are initiated locally but propagate into adjacent tissues. 266 Diffusing Ca 2+ ions activate neighboring SR, which in turn triggers further Ca 2+ release from SR. These Ca 2+ waves may give rise to premature contractions and trigger arrhythmias. 267 Purkinje fibers are particularly prone to proarrhythmic [Ca] 2+ i waves and may serve as an arrhythmia focus for injured myocardium. 268 Another potential mechanism underling arrhythmogenic Ca 2+ waves are the activation of stretch-activated channels, which are nonselective cation channels activated by mechanical stress. 269 In the MDX mouse, lack of dystrophin results in increased activity of stretchactivated channels and increased resting intracellular [Ca] 2+ i in skeletal muscles. 270 Stretch-activated channels also have been reported in ventricular cardiomyocytes 271 and are proposed to play a role in tachycardia-induced chronic heart failure. 272 Thus, the role of Ca 2+ in maladaptive contractions may be proarrhythmic.
Therapeutic Targets for Heart Failure
Current drug therapies for CHF are mainly designed to counteract overactivation of the sympathetic and renin angiotensinaldosterone systems, which is known to prolong survival. [247] [248] [249] Advanced CHF associated with increased risk of fatal arrhythmias also can be managed by surgically implantable cardioverter defibrillator, cardiac resynchronization therapy, and mechanical ventricular assist devices. However, currently available pharmacological and device therapies are far from ideal because they fail to fully correct underlying molecular abnormalities involved in systolic and diastolic dysfunction as well as adverse structural and proarrhythmic electric remodeling. Given the central role of Ca 2+ signaling in the progression of CHF, restoration of normal [Ca] 2+ i homeostasis is a promising strategy to forestall progression and improve function of failing cardiomyocytes.
RyR2
CHF is a condition of leaky RyR2, decreased SR Ca 2+ content, and reduced [Ca] 2+ i transients. Leaky RyR2 can contribute to myocardial dysfunction and arrhythmias. 58, 238 Overexpression of the RyR2 regulatory protein FKBP12.6 caused increased SR Ca 2+ content and improved myocyte shortening in isolated cardiomyocytes. 238 RyR2 leak also can potentially be directly targeted by pharmacological agents shown to improve cardiac function 238 and prevent arrhythmias. 275 For example, K201, a benzothiazepine derivative and inhibitor of RyR2 was shown to stabilize RyR2s and decrease SR Ca 2+ leak. 274 So-called Rycals, K201-congeners, have emerged as promising agents for targeting RyR2 and reducing arrhythmias and heart failure. 36 Another Rycal compound, ARM036, also a benzothiazepine derivative, is in phase II trials for heart failure and catecholaminergic polymorphic ventricular tachycardia. It is anticipated that information regarding the potential clinical benefits of pharmacological therapy aiming to modulate RyR2 function will soon become available.
Ca 2+ -Dependent and Calmodulin-Dependent Protein Kinase II
CaMKII links Ca 2+ homeostasis and cardiac function in myocardium under physiological conditions. Under pathological conditions such as heart failure characterized by excessive neurohormonal activation and oxidative stress, CaMKII activation is sustained, which promotes diastolic Ca 2+ leak and arrhythmias. Animal studies consistently demonstrate that CaMKII inhibition reduces heart failure and arrhythmias, reducing or preventing sudden death. In our view, CaMKII is a highly validated target that connects to most or all aspects of defective [Ca] 2+ i homeostasis in heart failure. However, to determine whether the experimentally observed benefits of CaMKII inhibition are applicable to human heart failure, CaMKII inhibitory drugs with drug-like properties and adequate specificity and safety will need to be developed.
Protein Kinase C
PKCα has been identified to have critical roles in the pathogenesis of heart failure. Deletion of the PKCα gene 216, 275 or inhibition with drugs 133, 276, 277 have shown dramatic protective effects against the development of heart failure of various etiologies, including ischemia, pressure overload, or dilated cardiomyopathy induced by deleting LIM protein in animal models. However, clinical trials with PKC inhibitors or receptors for activated C kinase inhibitor peptides were largely disappointing for improving heart failure 278 or reducing myocardial injury in MI patients. 279, 280 Transfer of genes encoding S100A1 and SERCA2a are discussed elsewhere in this compendium.
Conclusion
It is now clear that impaired [Ca] 2+ i homeostasis is a key feature of heart failure that contributes to contractile dysfunction and arrhythmias. Defective Ca 2+ homeostasis in heart failure is most often the result of altered expression and function of a group of [Ca] 2+ i -handling and structural proteins, ion channels, and enzymes. Numerous laboratories have contributed to the improved understanding of these pathways and this new knowledge has bolstered the quest to develop novel and improved therapeutics. We expect that the next several years will witness the initial results of several promising heart failure therapies designed to correct defects in myocardial [Ca] 2+ i homeostasis.
